Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
11.48
0.45 (4.08%)
At close: Jun 06, 2025, 3:59 PM
11.50
0.17%
After-hours: Jun 06, 2025, 05:59 PM EDT
4.08% (1D)
| Bid | 9.9 |
| Market Cap | 626.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -90.06M |
| EPS (ttm) | -1.67 |
| PE Ratio (ttm) | -6.87 |
| Forward PE | -4.21 |
| Analyst | Buy |
| Ask | 11.99 |
| Volume | 1,034,735 |
| Avg. Volume (20D) | 849,523 |
| Open | 11.20 |
| Previous Close | 11.03 |
| Day's Range | 10.37 - 11.84 |
| 52-Week Range | 7.80 - 28.09 |
| Beta | -2.39 |
About BCAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-40.8%
Bicara Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
2 weeks ago
+7.33%
Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.
2 weeks ago · seekingalpha.com
Bicara: Stock Decline On FICERA Abstract Release Creates Buying OpportunityThe recent stock drop in Bicara Therapeutics Inc. is an overreaction, as the full phase 1/1b data—including key OS results—has yet to be released. BCAX interim data for FICERA plus KEYTRUDA in HPV-neg...
